Shield Therapeutics

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Announcements

Webinars

Media

Portfolio

Publications

ID/IDA Facts and Figures

Approved Medicine

Careers

Partnerships

Contact and Locations

Overview

Leadership

Financials

Corporate Governance

Analysts & Advisors

AIM Rule 26

Stock Information

Investor Overview

Noto Sans

Q1 Trading Update

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag take Proactive's Stephen Gunnion through the company's impressive growth in the iron deficiency market. They discussed the key highlights from the first half of the year, including a 3.5x increase in Accrufer revenues, bringing in $11 million in total net revenue. Shanbhag emphasised this growth was driven by both increased prescriptions and improved pricing strategies.  

Lundstrom provided insights into Shield Therapeutics' broader market strategy, focusing on their collaboration with Viatris and global partners to expand Accrufer's reach. He highlighted recent milestones such as Health Canada's approval of Accrufer, marking a significant step in the company's global expansion.  

Shanbhag further detailed Shield's financial positioning, including maintaining $8.1 million in cash and strategic financing moves to support ongoing growth. As Shield Therapeutics continues to penetrate the US market and explore new opportunities worldwide, investors should stay tuned for updates on their strategic initiatives and upcoming pediatric study results.  

Shield Therapeutics wraps up strong first half as Accrufer gains more traction in the US